钆基对比剂钆塞酸二钠的不良事件:系统综述与Meta分析
该系统综述与Meta分析检索多数据库,纳入报告钆塞酸二钠增强MRI不良事件的研究,17项研究报告14850次给药中超敏反应发生率0.3%(31/14850,95%CI 0.2%-0.4%),无死亡;4项研究报告106次严重肾功能不全患者给药,NSF风险95%CI上限为2.8%。作者结论认为钆塞酸二钠的超敏反应和NSF安全性特征与美国放射学会2组钆基对比剂相似,但因严重肾功能不全患者给药例数较少,NSF风险置信度较低;颅内钆沉积信息不完整。
要点
- 17项研究14850次给药中超敏反应发生率0.3%(31/14850,95%CI 0.2%-0.4%),无死亡。
- 4项研究106次严重肾功能不全患者给药,NSF风险95%CI上限为2.8%。
- 5项评估颅内钆沉积的研究均存在高偏倚风险,信息不完整。
核心结论
- 钆塞酸二钠的超敏反应和NSF安全性特征与美国放射学会2组钆基对比剂相似,但因严重肾功能不全患者给药例数较少,NSF风险置信度较低。
- 记录钆塞酸二钠给药后颅内钆沉积的信息不完整。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE(1946-2019)、Embase(1947-2019)、CENTRAL(2019年3月)和Scopus(1946-2019),方案注册于Prospero(编号162811)。
- 纳入报告钆塞酸二钠增强MRI不良事件的原研究、病例系列和病例报告;71项研究进行全文审查。
- 采用QUADAS-2评估偏倚风险,采用随机效应模型进行比例Meta分析,并确定NSF风险95%CI上限。
诊断标准与关键数值
- 17项研究报告14850次给药,超敏反应发生率为0.3%(31/14850;95%CI 0.2%,0.4%),死亡为零。
- 4项研究报告106次给药于4期或5期慢性肾脏病或透析患者,NSF风险95%CI上限为2.8%。
- 5项评估钆塞酸二钠给药后颅内钆滞留的研究存在高偏倚风险。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 因严重肾功能不全患者给药例数较少,NSF风险置信度较低。
- 记录钆塞酸二钠给药后颅内钆沉积的信息不完整。
- 评估颅内钆滞留的5项研究存在高偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Gadoxetic acid is classified by the American College of Radiology as a group III gadolinium-based contrast agent (GBCA), which indicates that there are limited data regarding nephrogenic systemic fibrosis (NSF) risk, but there are few if any unconfounded cases of NSF. Purpose To perform a systematic review and meta-analysis of gadoxetic acid adverse events, including immediate hypersensitivity reactions, NSF, and intracranial gadolinium retention. Materials and Methods Original research studies, case series, and case reports that reported adverse events in patients undergoing gadoxetic acid-enhanced MRI were searched in MEDLINE (1946-2019), Embase (1947-2019), CENTRAL (March 2019), and Scopus (1946-2019). The study protocol was registered at Prospero (number 162811). Risk of bias was evaluated by using Quality Assessment of Diagnostic Accuracy Studies-2, or QUADAS-2. Meta-analysis of proportions was performed by using random-effects modeling. Upper bound of 95% confidence interval (CI) for risk of NSF was determined. Results Seventy-one studies underwent full-text review. From 17 studies reporting 14 850 administrations, hypersensitivity reactions occurred in 0.3% (31 of 14 850; 95% CI: 0.2%, 0.4%) with zero deaths. From four studies reporting 106 administrations in patients with stage 4 or 5 chronic kidney disease or undergoing dialysis, the upper bound 95% CI for the risk of NSF was 2.8%. Five studies evaluating intracranial retention of gadolinium after gadoxetic acid administration were at high risk of bias. Conclusion Gadoxetic acid had a similar safety profile to American College of Radiology group 2 gadolinium-based contrast agents for hypersensitivity reactions and nephrogenic systemic fibrosis (NSF) but had lower confidence for risk of NSF because of fewer administrations in patients with severe kidney impairment. There is incomplete information documenting intracranial gadolinium retention in patients administered gadoxetic acid. © RSNA, 2020 Online supplemental material is available for this article.
引用
- Schieda N, van der Pol CB, Walker D, et al. Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis. Radiology. 2020. PMID: 32452732. doi:10.1148/radiol.2020200073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。